Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments

Rhea-AI Summary

Philips (NYSE:PHG) introduced Rembra on March 4, 2026 — a CE-marked, 510(k)-pending CT system built for acute and high-demand imaging.

Key specs: up to 106 images/sec, throughput up to 270 patients/day, largest-in-class 85 cm bore, NanoPanel Precise XD detector with 23 lp/cm resolution and 0.25 mm detail, and a Tube for Life program covering tube replacement up to 10 years.

Positive

• Reconstruction speed up to 106 images per second
• High throughput capacity up to 270 patients per day
• Largest-in-class 85 cm bore for complex positioning and access
• Detector resolution of 23 line pairs per cm enabling 0.25 mm detail
• Tube for Life program covering tube replacement up to 10 years

Negative

• 510(k) pending — not yet available for sale in the USA
• 85 cm EFOV is not for diagnostic use, only treatment planning
• Throughput estimate based on 16-hour day testing, may vary in practice

Key Figures

Reconstruction speed: 106 images per second Daily throughput: 270 patients per day Gantry bore size: 85 cm bore +5 more

8 metrics

Reconstruction speed 106 images per second Rembra CT reconstruction performance

Daily throughput 270 patients per day Rembra CT high-demand imaging capacity

Gantry bore size 85 cm bore Largest-in-class patient access for CT system

Standard field of view 60 cm sFOV Standard imaging field for Rembra CT

Extended field of view 85 cm eFOV Extended field for radiation therapy planning

Scan range 2.3 meters Patient table scan range for Rembra CT

Spatial resolution 23 line pairs per cm In‑plane spatial resolution of NanoPanel Precise XD detector

Anatomical detail size 0.25 mm Smallest anatomical structures visualized by Rembra CT

Market Reality Check

Price: $30.34 Vol: Volume 954,706 is below t...

normal vol

$30.34 Last Close

Volume Volume 954,706 is below the 20-day average of 1,329,872 (relative volume 0.72). normal

Technical Shares at $30.34 trade above the 200-day MA of $27.14 and 9.26% below the 52-week high of $33.435.

Peers on Argus

PHG fell 2.63% while key medical device peers were mixed, with small moves rangi...

1 Down

PHG fell 2.63% while key medical device peers were mixed, with small moves ranging from about -0.09% (STE) to +1.46% (SNN). Momentum scanner flagged only SYK moving down, suggesting a stock-specific reaction rather than a broad sector move.

Historical Context

5 past events · Latest: Feb 19 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 19	Annual report filing	Neutral	-1.6%	Publication of the Annual Report 2025 and AGM agenda details.
Feb 12	Product launch	Positive	-2.1%	Introduction of Snuggle pediatric MRI coil with FDA 510(k) clearance.
Feb 10	Earnings and targets	Positive	+11.1%	Full-year 2025 results with growth, margin expansion and new 2026–2028 targets.
Feb 10	Leadership update	Positive	+11.1%	Proposal to re-appoint CEO Roy Jakobs following reported productivity savings.
Jan 29	Industry award	Positive	+0.8%	Frost & Sullivan award for digital pathology–healthcare informatics capabilities.

Pattern Detected

Recent Philips headlines around technology launches, awards and management/strategy have more often seen positive or modestly positive price reactions, with one notable divergence where product news coincided with a share decline.

Recent Company History

Over the last few months, Philips has reported multiple milestones. On Jan 29, 2026, it received a Frost & Sullivan technology leadership award, followed by strong 2025 results and new 2026–2028 targets and a proposed CEO re-appointment on Feb 10, both linked to double‑digit gains. Subsequent product and reporting updates, including the pediatric MRI coil and the Annual Report 2025, saw modest declines. Today’s CT system launch fits the pattern of continued innovation news in imaging.

Market Pulse Summary

This announcement highlights Philips’ continued focus on advanced imaging, with Rembra targeting acu...

Analysis

This announcement highlights Philips’ continued focus on advanced imaging, with Rembra targeting acute and high-demand CT environments using AI-enabled workflows, an 85 cm bore and reconstruction speeds up to 106 images per second. In recent months, Philips has paired such product updates with strategic and financial disclosures. Investors may watch how new CT platforms complement earlier initiatives in MRI and digital pathology and how adoption trends feed into future revenue and margin discussions.

Key Terms

ce marked, 510(k), bariatric, anti-scatter grid, +2 more

6 terms

ce marked regulatory

"March 4, 2026 CE Marked and 510(k) pending, Rembra’s advanced image..."

CE marked indicates that a product meets European Union safety, health and environmental requirements and bears the CE symbol, acting like a safety stamp or passport that allows the product to be sold across the EU and European Economic Area. For investors, a CE mark matters because it reduces regulatory barriers and legal risk, can speed market access and revenue, and signals the company has cleared essential compliance steps for that product—affecting sales potential, costs and valuation.

510(k) regulatory

"March 4, 2026 CE Marked and 510(k) pending, Rembra’s advanced image..."

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

bariatric medical

"providing more access for complex interventions, bariatric imaging and trauma..."

Bariatric describes medical treatments, devices or procedures aimed at helping people with severe obesity lose weight and reduce related health risks, including surgical operations, implanted devices and newer drug or endoscopic therapies. Investors care because bariatric products sit at the intersection of healthcare demand, regulatory approval and payer coverage—like a major home renovation that can both improve immediate function and change long‑term costs—so market size, reimbursement rules and clinical results drive sales and valuation.

anti-scatter grid technical

"A 2D anti-scatter grid provides strong scatter rejection to help preserve..."

An anti-scatter grid is a thin device placed between the patient and an X‑ray detector that acts like a picket fence for stray X‑ray beams, blocking scattered rays while letting straight‑line rays through. By improving image contrast and clarity, it makes diagnostic images more reliable; for investors this affects a medical imaging product’s clinical value, competitive position, regulatory acceptance, and potential sales or servicing costs.

spectral ct medical

"Also making its European debut at ECR 2026 is Verida, the world’s first detector-based spectral CT powered by AI."

Spectral CT is an advanced form of X‑ray scanning that separates the different energy “colors” of X‑rays to tell materials apart inside the body, similar to how a prism splits light into colors so you can identify substances. For investors, it matters because it can produce clearer images, reduce contrast dose or repeat scans, and enable new diagnostic capabilities, potentially driving demand for upgraded scanners and related software in hospitals and clinics.

detector-based technical

"Also making its European debut at ECR 2026 is Verida, the world’s first detector-based spectral CT powered by AI."

A detector-based system uses a physical device or component to sense and measure a specific signal—such as light, electrical current, particles, or chemical markers—and converts that signal into readable data. For investors, detector-based products matter because they are often core to diagnostic tests, sensors, or safety equipment; their accuracy, cost, and manufacturing scalability directly affect product performance, regulatory approval, and market potential, much like a camera’s sensor determines photo quality and value.

AI-generated analysis. Not financial advice.

March 4, 2026

• CE Marked and 510(k) pending, Rembra’s advanced image reconstruction technology delivers up to 106 images per second [1] and a high throughput of up to 270 patients per day [2] to support faster diagnosis by making scans available in near-real time
• With the largest-in-class 85 cm bore, Rembra accommodates challenging patient types, providing more access for complex interventions, bariatric imaging and trauma, helping to improve comfort for complex patients and may reduce the need for rescans
• Next-generation NanoPanel Precise XD detector with AI is built for dose-efficient, high-resolution imaging to support clear visualization and delineation of anatomical structures

Amsterdam, the Netherlands and Vienna, Austria – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced Rembra [3], its next-generation radiology CT system designed for the realities of acute and high-demand imaging. Rembra will be showcased publicly for the first time at ECR 2026 in Vienna.

Healthcare systems worldwide are under unprecedented pressure. Rising patient volumes, increasing clinical complexity and workforce shortages are pushing frontline, high-acuity and high-demand imaging to its limits. Rembra was engineered from the ground up to meet these challenges, bringing together advanced detector technology, ultra-fast scan and reconstruction speeds and streamlined workflows in a system built for speed, consistency and long-term value.

“Rembra is built for the realities that clinicians face every day,” said Dan Xu, Business Leader for Computed Tomography at Philips. “By combining our most advanced detector technology with AI-powered workflows and industry-leading speed, Rembra represents a significant step forward for high-acuity imaging, delivering speed, access and diagnostic confidence when it matters most.”

Industry-leading speed [1] to support timely clinical decisions
In emergency, trauma and other high-demand settings, delays in image reconstruction can slow diagnosis and impact outcomes. Rembra addresses this challenge with an industry-leading reconstruction speed – up to 106 images per second [1]. This speed is designed to help radiologists and clinicians access images quickly in stroke, trauma and other urgent cases. It may support smoother workflows and timely clinical decisions in busy emergency departments.

Designed for high-demand environments, Rembra can support 270 exams per day [2], helping imaging departments manage growing volumes without compromising speed or confidence.

Optimized patient positioning and access
With the largest-in-class 85 cm bore, Rembra is designed to help facilitate patient access and positioning, and may help improve comfort for trauma, bariatric and interventional cases.

Rembra features a 60 cm standard field of view (sFOV) and an 85 cm extended field of view (eFOV), both the largest in their class of frontline radiology CT systems [4], enabling full anatomical visualization in a single scan. Rembra also features a high-performance patient table with Philips’ best-in-class scan range of up to 2.3 meters and gantry-to-tablespace of 46 cm to support flexible patient positioning.

“In interventional and high acuity settings, precise access and efficient positioning are essential,” said Professor Olivier Rouvière, MD, PhD, Head of Department at Hospices Civils de Lyon (Centre Hospitalier Universitaire de Lyon). “Rembra’s 85 cm bore supports improved access as well as faster and safer positioning of long needles and instruments in complex procedures.”

Clinical performance without compromise
At the heart of Rembra is Philips’ newest NanoPanel Precise XD, a high-density detector designed from the outset to work hand-in-hand with AI. It delivers high dose-efficiency, high-resolution imaging at the source and is designed to support overall image quality and diagnostic confidence.

The detector offers exceptional in-plane spatial resolution of 23 line pairs per cm, enabling sharp detail and visualization of fine anatomical structures down to 0.25 mm. A 2D anti-scatter grid provides strong scatter rejection to help preserve image clarity in challenging patient types, supporting consistently high image quality across patient sizes and clinical scenarios.

AI-designed for productivity, predictability and long-term value
Integrated AI-enabled smart workflows can help automate routine steps and simplify certain operations. These features are intended to support workflow efficiency for consistent results.

Built for operations at high-altitude environments up to 5000m, Rembra is engineered for reliability, durability and long-term performance, supporting a system lifetime of up to 20 years with required maintenance and upgrades. Philips’ industry-first Tube for Life [5] service program further enhances cost predictability by covering tube replacement costs for up to 10 years.

Advancing spectral CT leadership
Also making its European debut at ECR 2026 is Verida, the world’s first detector-based spectral CT powered by AI. Verida integrates AI across the entire imaging chain. First introduced at RSNA 2025, Verida delivers exceptional spectral image quality while helping to accelerate workflows and reduce dose, further reinforcing Philips’ leadership in spectral CT innovation [6,7]. For more information about Verida, please visit the Verida spectral-detector CT scanner page.

[1] Based on publicly available manufacturer specifications for leading radiology CT systems as of March 2026 on reconstruction speed in this class of scanners and bore size.
[2] Based on a sixteen-hour day, with throughput testing with 203 patient scans/ 12 hours for Rembra with typical radiological profiles and protocols.
[3] Pending 510(k) - not available for sale in the USA
[4] The Extended Field of View (EFOV) of 85 cm is intended solely for use in treatment preparation and the planning/simulation of radiation therapy. It cannot be used for diagnostic purposes. The water equivalent material external contour deviation of body system phantom positioned (partially) outside scan FOV with phantom edge adjacent to bore cover shall be within 1mm in terms of mean Hausdorff distance compared to the true external contour.
[5] Tube for Life guarantee availability varies by country. Please contact your local Philips sales representative for details
[6] Andersen MB et al. Impact of spectral body imaging in patients suspected for occult cancer: a prospective study of 503 patients. Eur Radiol2020. doi.org/10.1007/s00330-020-06878-7
[7] Andersen MB et al. Economic impact of spectral body imaging in the diagnosis of patients suspected of occult cancer. Insights into Imaging 2021. doi.org/10.1186/s13244-021-01116-0. Results of customer testimonies are not predictive of results in other cases, where results may vary.

For further information, please contact:
Jayme Maniatis 
Philips Global External Relations  
Tel.: +1 617 804 8368
E-mail: Jayme.maniatis@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips unveils Rembra CT at ECR 2026
• Philips Rembra, a next-generation radiology CT system designed for the realities of acute and high-demand imaging

FAQ

What are the reconstruction speed and throughput claims for Philips Rembra (PHG) announced March 4, 2026?

Rembra offers up to 106 images per second and throughput up to 270 patients per day. According to Philips, speeds derive from manufacturer specifications and internal 16-hour throughput testing with typical protocols.

Does Philips Rembra (PHG) support large or bariatric patients with its 85 cm bore?

Yes, Rembra features an 85 cm bore designed to improve access and positioning for bariatric and trauma patients. According to Philips, the bore plus 60 cm sFOV and 85 cm eFOV enable full anatomical visualization in a single scan for treatment planning.

What detector technology and image detail does Philips Rembra (PHG) use for clinical imaging?

Rembra uses the NanoPanel Precise XD detector delivering 23 line pairs/cm and visualization down to 0.25 mm. According to Philips, the detector is AI-integrated for dose-efficient, high-resolution imaging and improved anatomical delineation.

Is Philips Rembra (PHG) available for sale in the United States after the March 4, 2026 announcement?

No, Rembra is CE marked but 510(k) is pending, so it is not available for sale in the USA. According to Philips, US availability depends on completion of the pending 510(k) clearance.

What service and longevity features does Philips offer with Rembra (PHG)?

Philips positions Rembra for long-term operations with an engineered lifetime up to 20 years and a Tube for Life program covering tube replacement for up to 10 years. According to Philips, availability of Tube for Life varies by country.

How should hospitals interpret the reported 270 patients-per-day capacity for Philips Rembra (PHG)?

The 270-per-day figure is a throughput estimate based on a 16-hour testing day with typical protocols and 203 scans per 12 hours. According to Philips, actual throughput will depend on local workflows, protocols, and staffing.